TENX
Tenax Therapeutics, Inc. NASDAQ$13.32
Mkt Cap $229.1M
52w Low $5.33
61.2% of range
52w High $18.38
50d MA $13.75
200d MA $10.12
P/E (TTM)
-9.5x
EV/EBITDA
-6.7x
P/B
5.2x
Debt/Equity
0.0x
ROE
-54.2%
P/FCF
-13.4x
RSI (14)
—
ATR (14)
—
Beta
1.19
50d MA
$13.75
200d MA
$10.12
Avg Volume
368.1K
About
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved eje…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -1.26 | -0.38 | +69.8% | 14.51 | +1.6% | +0.8% | -2.2% | -4.6% | -3.7% | +4.5% | — |
| Nov 12, 2025 | AMC | -1.33 | -0.40 | +69.9% | 6.99 | -1.7% | -4.3% | +1.6% | +5.2% | +10.0% | +4.7% | — |
| Aug 13, 2025 | AMC | -0.50 | -0.27 | +46.0% | 5.91 | -1.5% | +0.7% | +1.0% | +1.7% | +1.9% | +1.2% | — |
| May 14, 2025 | AMC | -0.48 | -0.28 | +41.7% | 5.68 | +1.2% | +0.4% | +3.7% | +6.0% | +5.6% | +6.9% | — |
| Mar 25, 2025 | AMC | -0.52 | -0.18 | +65.4% | 6.26 | +7.2% | -2.1% | -1.3% | +3.7% | +4.6% | +1.6% | — |
| Nov 13, 2024 | AMC | -1.38 | -0.19 | +86.2% | 4.75 | +2.1% | +4.0% | +2.5% | +1.7% | +2.3% | +0.4% | — |
| Aug 13, 2024 | AMC | -1.99 | -1.83 | +8.0% | 4.03 | -0.7% | -2.0% | -0.7% | +4.0% | +5.5% | +2.7% | — |
| May 14, 2024 | AMC | -2.40 | -3.12 | -30.0% | 3.47 | +4.0% | +3.5% | +2.3% | +2.3% | +8.6% | +5.8% | — |
| Mar 28, 2024 | AMC | -8.14 | -12.98 | -59.5% | 4.24 | -2.1% | -9.9% | -8.7% | -3.1% | -9.9% | -9.9% | — |
| Nov 13, 2023 | AMC | -7.20 | -6.40 | +11.1% | 49.60 | -17.7% | -18.5% | -19.5% | -32.3% | -38.5% | -41.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16 | Guggenheim | Maintains | Buy → Buy | — | $13.84 | $14.42 | +4.2% | +1.0% | +9.6% | +12.5% | +7.7% | +3.3% |
| Dec 17 | Guggenheim | Maintains | Buy → Buy | — | $11.16 | $11.30 | +1.3% | +5.6% | +14.9% | +17.4% | +11.6% | +7.2% |
| Aug 14 | Guggenheim | Maintains | Buy → Buy | — | $5.91 | $5.82 | -1.5% | +0.7% | +1.0% | +1.7% | +1.9% | +1.2% |
| Feb 20 | Roth MKM | Maintains | Buy → Buy | — | $4.15 | $4.23 | +1.9% | -3.9% | +4.8% | -1.7% | -4.1% | -4.8% |
| Nov 13 | Roth MKM | Maintains | Buy → Buy | — | $12.48 | $25.04 | +100.6% | +297.4% | +223.7% | +219.9% | +169.2% | +144.2% |
| May 18 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $15712.00 | $15936.00 | +1.4% | -1.2% | +2.4% | +4.9% | +4.7% | +5.9% |
Recent Filings
8-K
Tenax Therapeutics, Inc. -- 8-K Filing
Tenax Therapeutics' CFO previously led Triangle Pharmaceuticals through its acquisition by Gilead Sciences, demonstrating experience navigating pharma M&A transactions that could benefit Tenax shareholders.
Apr 22
8-K
Unknown — 8-K Filing
TENX's achievement of randomization targets in its Phase 3 LEVEL study positions potential approval within 18 months, while concurrent LEVEL-2 initiation signals confidence in the drug's viability and reduces development risk for investors.
Mar 10
Data updated apr 27, 2026 4:27am
· Source: massive.com